{"id":"mmf-immunosuppression","safety":{"commonSideEffects":[{"rate":"30%","effect":"Diarrhea"},{"rate":"20%","effect":"Nausea"},{"rate":"15%","effect":"Vomiting"},{"rate":"10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL102817","moleculeType":"Small molecule","molecularWeight":"363.37"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"MMF works by inhibiting the enzyme inosine monophosphate dehydrogenase (IMPDH), which is involved in the synthesis of guanine nucleotides. This leads to a decrease in the proliferation of T and B lymphocytes.","oneSentence":"Inhibits inosine monophosphate dehydrogenase (IMPDH)","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:39:11.138Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in kidney transplant patients"}]},"trialDetails":[{"nctId":"NCT02579967","phase":"PHASE2","title":"Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-19","conditions":"Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, Immune System Diseases","enrollment":354},{"nctId":"NCT06033196","phase":"PHASE2","title":"Tocilizumab in Lung Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-02-13","conditions":"Lung Transplant","enrollment":350},{"nctId":"NCT04464434","phase":"PHASE4","title":"Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-09-17","conditions":"Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma","enrollment":60},{"nctId":"NCT04990323","phase":"PHASE1, PHASE2","title":"US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies","status":"COMPLETED","sponsor":"ExCellThera inc.","startDate":"2021-12-01","conditions":"High Risk Myeloid Malignancies, Cord Blood Transplant","enrollment":13},{"nctId":"NCT07491523","phase":"","title":"Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD","status":"RECRUITING","sponsor":"University of Patras","startDate":"2025-06-01","conditions":"SSc-Systemic Sclerosis","enrollment":35},{"nctId":"NCT04103879","phase":"PHASE2","title":"US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia","status":"COMPLETED","sponsor":"ExCellThera inc.","startDate":"2020-11-13","conditions":"High Risk Hematological Malignancy, Cord Blood Transplant","enrollment":30},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT06568549","phase":"PHASE4","title":"Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-06-13","conditions":"Kidney Transplantation, Mycophenolate Mofetil","enrollment":350},{"nctId":"NCT03323476","phase":"PHASE3","title":"Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Departemental Vendee","startDate":"2018-02-02","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, End Stage Renal Disease","enrollment":136},{"nctId":"NCT06354179","phase":"PHASE4","title":"Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)","status":"RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2025-04-15","conditions":"Liver Transplantation, Immunosuppression","enrollment":162},{"nctId":"NCT06503731","phase":"PHASE2","title":"A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)","status":"RECRUITING","sponsor":"argenx","startDate":"2024-08-30","conditions":"Antibody-mediated Rejection","enrollment":30},{"nctId":"NCT03663933","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-04","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders","enrollment":71},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT04644016","phase":"PHASE2","title":"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-11-20","conditions":"AML, ALL, MDS","enrollment":31},{"nctId":"NCT06365437","phase":"PHASE2","title":"A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation","status":"TERMINATED","sponsor":"ITB-Med LLC","startDate":"2021-06-06","conditions":"Kidney Transplantation","enrollment":33},{"nctId":"NCT05736419","phase":"PHASE2","title":"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-02-09","conditions":"Sickle Cell Disease, Thalassemia, Beta, Thalassemia","enrollment":24},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT00619528","phase":"NA","title":"HLA-Identical Sibling Renal Transplant Tolerance","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2008-01","conditions":"Immunosuppression, Kidney Transplantation, Graft Rejection","enrollment":88},{"nctId":"NCT07430683","phase":"PHASE4","title":"Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Guadalajara","startDate":"2024-03-01","conditions":"Cytomegalovirus Infections","enrollment":68},{"nctId":"NCT05156710","phase":"PHASE2","title":"BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-06-09","conditions":"Transplant Rejection","enrollment":48},{"nctId":"NCT01203722","phase":"PHASE1, PHASE2","title":"Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-09","conditions":"Hematologic Malignancies","enrollment":87},{"nctId":"NCT03480360","phase":"PHASE3","title":"Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2018-03-28","conditions":"Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia","enrollment":21},{"nctId":"NCT05432765","phase":"NA","title":"AIIM Trial: Personalized Medicine Approach to Kidney Allograft Function","status":"NOT_YET_RECRUITING","sponsor":"University of Florida","startDate":"2026-12","conditions":"Kidney Transplant Rejection","enrollment":34},{"nctId":"NCT02081755","phase":"PHASE4","title":"Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Baylor Research Institute","startDate":"2014-03","conditions":"Carcinoma, Hepatocellular","enrollment":336},{"nctId":"NCT04180059","phase":"PHASE1","title":"Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2020-02-09","conditions":"Haematologic Disease","enrollment":6},{"nctId":"NCT06663046","phase":"EARLY_PHASE1","title":"Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma","status":"RECRUITING","sponsor":"Wondercel Biotech (ShenZhen)","startDate":"2025-07-01","conditions":"Multiple Myleoma, Refractory and Relapsed Multiple Myeloma","enrollment":30},{"nctId":"NCT06653023","phase":"EARLY_PHASE1","title":"Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer","status":"RECRUITING","sponsor":"Wondercel Biotech (ShenZhen)","startDate":"2024-10-23","conditions":"HCC - Hepatocellular Carcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":60},{"nctId":"NCT06662227","phase":"EARLY_PHASE1","title":"Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors","status":"RECRUITING","sponsor":"Wondercel Biotech (ShenZhen)","startDate":"2024-10-24","conditions":"B Cell Lymphoma, B Cell Leukemia, B Cell Malignancy","enrollment":30},{"nctId":"NCT04187105","phase":"PHASE2","title":"BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2020-01-27","conditions":"Acute Leukemia, MDS","enrollment":27},{"nctId":"NCT05669001","phase":"PHASE2","title":"A Study of TCD601 in de Novo Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITB-Med LLC","startDate":"2023-12-28","conditions":"Renal Transplantation","enrollment":76},{"nctId":"NCT05077254","phase":"PHASE2","title":"COVID Protection After Transplant-Immunosuppression Reduction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-06","conditions":"Kidney Transplant Recipients, Liver Transplant Recipients","enrollment":48},{"nctId":"NCT03922724","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-18","conditions":"Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases","enrollment":330},{"nctId":"NCT04104438","phase":"PHASE4","title":"Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant","status":"COMPLETED","sponsor":"Fady M Kaldas, M.D., F.A.C.S.","startDate":"2021-01-15","conditions":"Asses Immunosuppression Modulation on Renal Recovery Post LT","enrollment":71},{"nctId":"NCT02377193","phase":"PHASE4","title":"Simulect Versus ATG in Sensitized Renal Transplant Patient","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2013-09","conditions":"Renal Transplant Rejection","enrollment":60},{"nctId":"NCT01630850","phase":"NA","title":"Islet Transplantation in Patients With \"Brittle\" Type I Diabetes","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 1","enrollment":20},{"nctId":"NCT01241864","phase":"PHASE2","title":"Islet Transplantation in Type 1 Diabetic Kidney Allograft","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2010-12","conditions":"Diabetes Mellitus, Type 1","enrollment":10},{"nctId":"NCT05806749","phase":"PHASE1","title":"Immunological Tolerance in Patients With Mismatched Kidney Transplants","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2023-07-07","conditions":"End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection","enrollment":16},{"nctId":"NCT06881927","phase":"PHASE4","title":"Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-02-01","conditions":"Sepsis and Septic Shock, Acute Respiratory Failure, Kidney Transplant Recipients","enrollment":212},{"nctId":"NCT04773392","phase":"PHASE4","title":"Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2021-11-23","conditions":"Kidney Transplantation, Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT06265584","phase":"PHASE2","title":"Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-08","conditions":"Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders","enrollment":56},{"nctId":"NCT02444429","phase":"PHASE3","title":"3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-09-02","conditions":"Renal Transplantation","enrollment":346},{"nctId":"NCT03216967","phase":"PHASE4","title":"Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2018-01-15","conditions":"BK Virus Nephropathy After Kidney Transplantation","enrollment":130},{"nctId":"NCT06478017","phase":"PHASE2","title":"Belatacept in Heart Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-01-29","conditions":"Heart Transplant","enrollment":66},{"nctId":"NCT01284725","phase":"PHASE3","title":"Weaning of Immunosuppression in Nephritis of Lupus","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2011-02-16","conditions":"Nephritis of Lupus","enrollment":100},{"nctId":"NCT05823571","phase":"PHASE1","title":"Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-07-06","conditions":"Leukemia, Acute, Myelodysplastic Syndromes, Myelomonocytic Leukemia, Chronic","enrollment":32},{"nctId":"NCT05570409","phase":"PHASE2, PHASE3","title":"Immunosuppressive Treatment in Chronic Virus-Negative Inflammatory Cardiomyopathy","status":"TERMINATED","sponsor":"LMU Klinikum","startDate":"2023-03-28","conditions":"Inflammatory Cardiomyopathy","enrollment":9},{"nctId":"NCT07074951","phase":"NA","title":"Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2013-03-10","conditions":"Primary IgA-nephropathy, High-risk, Caucasians","enrollment":240},{"nctId":"NCT06829719","phase":"NA","title":"TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-04-23","conditions":"Infection, Cancer, Rejection","enrollment":300},{"nctId":"NCT04953715","phase":"","title":"Microbiome and Immunosuppression: The Mission Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2020-02-12","conditions":"Kidney Transplant Rejection, Kidney Transplant","enrollment":140},{"nctId":"NCT06280950","phase":"PHASE2","title":"Expanding Liver Transplant Immunosuppression Minimization Via Everolimus","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-12","conditions":"Liver Transplant","enrollment":340},{"nctId":"NCT03828019","phase":"PHASE3","title":"Adalimumab vs. Conventional Immunosuppression for Uveitis Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2019-09-16","conditions":"Uveitis","enrollment":227},{"nctId":"NCT03781414","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-10-07","conditions":"Liver Transplant Rejection","enrollment":129},{"nctId":"NCT06950931","phase":"","title":"Posttranslationally Modified Fetuin-A in Urine as a Marker for Renal Dysfunction (Patients With Chronic Kidney Disease - With or Without Kidney Transplantation).","status":"ENROLLING_BY_INVITATION","sponsor":"University Hospital, Martin","startDate":"2024-06-25","conditions":"Transplant Recipient (Kidney), Primary Kidney Transplantation","enrollment":86},{"nctId":"NCT05365672","phase":"PHASE2","title":"Clinical Trial With Donor Modified Immune Cells in Living Donor Kidney Transplantation","status":"RECRUITING","sponsor":"TolerogenixX GmbH","startDate":"2022-05-04","conditions":"Kidney Transplantation","enrollment":126},{"nctId":"NCT02711826","phase":"PHASE1, PHASE2","title":"Treg Therapy in Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-20","conditions":"Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant","enrollment":32},{"nctId":"NCT05060991","phase":"PHASE4","title":"Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2021-09-24","conditions":"COVID-19, Immunosuppression, Vaccine Response Impaired","enrollment":50},{"nctId":"NCT04469842","phase":"EARLY_PHASE1","title":"Early Use of Long-acting Tacrolimus in Lung Transplant Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-12-01","conditions":"Lung Transplant; Complications","enrollment":48},{"nctId":"NCT04311632","phase":"PHASE2","title":"A Dose Escalation Study in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"ITB-Med LLC","startDate":"2021-05-26","conditions":"Kidney Transplantation","enrollment":13},{"nctId":"NCT03555448","phase":"PHASE4","title":"Once Daily Immunosuppression Regimen","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2018-06-04","conditions":"Kidney Transplant; Complications","enrollment":51},{"nctId":"NCT04870359","phase":"NA","title":"Pre-emptive Treatments in Lupus Nephritis Patients With Serological Reactivation","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2016-04-21","conditions":"Lupus Nephritis","enrollment":49},{"nctId":"NCT06019507","phase":"PHASE2","title":"A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITB-Med LLC","startDate":"2022-06-29","conditions":"Liver Transplantation","enrollment":12},{"nctId":"NCT01011205","phase":"PHASE3","title":"Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-09-30","conditions":"Liver Transplantation","enrollment":893},{"nctId":"NCT00717470","phase":"PHASE4","title":"A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-05-14","conditions":"Kidney Transplantation","enrollment":1252},{"nctId":"NCT00933231","phase":"PHASE3","title":"Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-08-17","conditions":"Kidney Transplantation","enrollment":281},{"nctId":"NCT01304836","phase":"PHASE4","title":"A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-01-22","conditions":"Kidney Transplantation","enrollment":1166},{"nctId":"NCT01363752","phase":"PHASE4","title":"A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-03-08","conditions":"Kidney Transplantation","enrollment":853},{"nctId":"NCT04776850","phase":"EARLY_PHASE1","title":"Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-29","conditions":"Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia","enrollment":""},{"nctId":"NCT01002339","phase":"PHASE4","title":"Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation","status":"TERMINATED","sponsor":"Armando Torres Ramírez","startDate":"2010-02","conditions":"Diabetes Mellitus, Adult-Onset","enrollment":134},{"nctId":"NCT06646497","phase":"PHASE2","title":"Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-11-01","conditions":"Aplastic Anemia","enrollment":52},{"nctId":"NCT06584773","phase":"PHASE4","title":"Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2015-06","conditions":"Disorder Related to Renal Transplantation","enrollment":80},{"nctId":"NCT04989491","phase":"PHASE4","title":"Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2021-12-01","conditions":"Epstein-Barr Virus Infections","enrollment":120},{"nctId":"NCT04225988","phase":"PHASE4","title":"Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2020-01-09","conditions":"Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT03088709","phase":"PHASE2","title":"Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide","status":"TERMINATED","sponsor":"Loyola University","startDate":"2017-01-18","conditions":"Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome","enrollment":5},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT03654040","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at UCSF","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":"Liver Transplant","enrollment":42},{"nctId":"NCT02498977","phase":"PHASE4","title":"Liver Immunosuppression Free Trial","status":"TERMINATED","sponsor":"King's College London","startDate":"2015-10","conditions":"Transplantation, Liver","enrollment":116},{"nctId":"NCT04177095","phase":"PHASE4","title":"Immune Monitoring to Facilitate Belatacept Monotherapy","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-02-11","conditions":"Kidney Transplant Rejection, Immunosuppression","enrollment":17},{"nctId":"NCT05126849","phase":"PHASE2","title":"Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-01-06","conditions":"Refractory Idiopathic Aplastic Anemia, Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":31},{"nctId":"NCT06114953","phase":"PHASE4","title":"Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2023-01-01","conditions":"Kidney Transplant Immunosuppression","enrollment":152},{"nctId":"NCT06044558","phase":"","title":"Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics","status":"COMPLETED","sponsor":"LI YAN","startDate":"2022-09-01","conditions":"Kidney Transplant Patients","enrollment":507},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT00556933","phase":"PHASE4","title":"Improved Induction and Maintenance Immunosuppression in Kidney Transplantation","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2004-04-01","conditions":"End-stage Renal Disease","enrollment":180},{"nctId":"NCT01044745","phase":"PHASE2","title":"Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2009-12-10","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":20},{"nctId":"NCT05973734","phase":"PHASE1","title":"Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2023-10-01","conditions":"Islet Transplantation","enrollment":24},{"nctId":"NCT02409147","phase":"NA","title":"Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2016-01","conditions":"Uterus Transplant","enrollment":""},{"nctId":"NCT00896012","phase":"PHASE4","title":"Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2008-01","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT02416674","phase":"EARLY_PHASE1","title":"Vascularized Composite Allotransplantation for Treatment of Abdominal Wall Defects","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2015-03-01","conditions":"Abdominal Wall Defect","enrollment":10},{"nctId":"NCT04927390","phase":"PHASE2","title":"Mycophenolate in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)","status":"UNKNOWN","sponsor":"University College, London","startDate":"2021-12-08","conditions":"Systemic Sclerosis, Limited Cutaneous Systemic Sclerosis","enrollment":120},{"nctId":"NCT04414735","phase":"NA","title":"Impact of Photopheresis in the Prevention of Acute Rejection in Highly Sensitized de Novo Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Kidney Transplant Rejection","enrollment":30},{"nctId":"NCT01650545","phase":"PHASE1, PHASE2","title":"Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-07","conditions":"Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity","enrollment":21},{"nctId":"NCT04258423","phase":"PHASE3","title":"Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function","status":"TERMINATED","sponsor":"Indiana University","startDate":"2019-12-19","conditions":"Kidney Failure","enrollment":4},{"nctId":"NCT05073822","phase":"PHASE1, PHASE2","title":"NOMINATE/ Minimisation of Immunosuppression in Kidney Transplantation","status":"WITHDRAWN","sponsor":"University College, London","startDate":"2023-02-20","conditions":"Renal Transplant Rejection, Renal Transplant Infection","enrollment":""},{"nctId":"NCT03797196","phase":"PHASE4","title":"RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2019-07-29","conditions":"Renal Transplant Recipients, Elderly Patients, Immunosuppression","enrollment":374},{"nctId":"NCT05423496","phase":"NA","title":"KidneyCare Immuno-optimization in Renal Allografts (KIRA)","status":"WITHDRAWN","sponsor":"CareDx","startDate":"2022-08","conditions":"Kidney Transplant, Immunosuppression, Allograft","enrollment":""},{"nctId":"NCT03995901","phase":"PHASE3","title":"A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation","status":"TERMINATED","sponsor":"Talaris Therapeutics Inc.","startDate":"2019-10-25","conditions":"Transplanted Organ Rejection","enrollment":15},{"nctId":"NCT03438773","phase":"PHASE1","title":"Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"California Institute of Renal Research","startDate":"2018-07-11","conditions":"Kidney Transplant; Complications, Kidney Transplant Failure and Rejection","enrollment":50},{"nctId":"NCT00589316","phase":"PHASE1","title":"Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2007-10-05","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":26},{"nctId":"NCT05707520","phase":"","title":"Long-term Benefit of MPA in Liver Transplantation","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2022-12-04","conditions":"Liver Transplant Rejection, Immunosuppressant Adverse Reaction","enrollment":500},{"nctId":"NCT02623309","phase":"PHASE3","title":"Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients","status":"COMPLETED","sponsor":"Institut Paoli-Calmettes","startDate":"2016-02-23","conditions":"Hematologic Neoplasms","enrollment":108},{"nctId":"NCT05061303","phase":"","title":"Omeprazole and Famotidine in Chronic Dysfunction of the Transplanted Kidney","status":"UNKNOWN","sponsor":"Poznan University of Medical Sciences","startDate":"2021-10-17","conditions":"Kidney Rejection Transplant","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RITUXIMAB"],"phase":"phase_2","status":"active","brandName":"MMF Immunosuppression","genericName":"MMF Immunosuppression","companyName":"Wondercel Biotech (ShenZhen)","companyId":"wondercel-biotech-shenzhen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits inosine monophosphate dehydrogenase (IMPDH) Used for Prevention of organ rejection in kidney transplant patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}